In section Market Quotes

Biotech Hits Record Highs as Defensive Health Stocks Languish

Investors are dumping defensive health-care staples in favor of high-growth gambles, pushing the iShares Biotech Index to an all-time peak. While risk appetite surges across the broader market, stalwarts like UnitedHealth Group are retreating, signaling a sharp rotation away from the sector's traditional safety nets.

By Money Talk·June 30, 2026·2 min read·1,944 reads

Biotech Hits Record Highs as Defensive Health Stocks Languish

This shift marks a departure from the stability usually associated with health-care holdings. As traders chase volatility, evergreen companies are losing their appeal, leaving defensive names to settle in flat or negative territory.

Amid this broader market recalibration, Ipsen is doubling down on its growth strategy. The French pharmaceutical firm has moved to acquire Kartos Therapeutics in a transaction valued at up to $1.75 billion, a strategic play aimed at fortifying its oncology pipeline despite the cooling interest in conservative health-care assets.

Biotech Hits Record Highs as Defensive Health Stocks Languish

Comments (0)